氯沙坦与贝那普利对糖尿病肾病的临床疗效观察

目的观察血管紧张素转换酶抑制剂（ACEI）和血管紧张素Ⅱ受体拮抗剂（ARB）对糖尿病肾病的疗效。方法将98例糖尿病肾病患者随机分为A、B两组：A组47例,使用氯沙坦100 mg 1次/d;B组51例,使用贝那普利10 mg 1次/d。分别于治疗3个月后检测24 h尿白蛋白量和血肌酐值。结果两个治疗组在治疗3个月后2,4 h尿白蛋白量显著减少（P〈0.01）,血肌酐的指标也明显变化（P〈0.01）。而两组之间的疗效差异无统计学意义（P〉0.05）。结论 ACEI和ARB可显著延缓糖尿病肾病的进展。

Clinical observation of effects of losartan and benazepril on treating diabetic nephropathy

Objective To observe the efficacy of ACEI and ARB on treating diabetic nephropathy（DN）.Methods 98 patients with DN were randomly divided into two groups： group A（n=47） was treated with losartan 100mg once daily;group B（n=51） was treated with benazepril 10mg once daily.24 hour urine albumin quantity and serum creatinine were measured after 3 month of treatment.Results 24-hour urinary albumin is significantly reduced in two treatment groups after 3 months of treatment,（P0.01） and creatinine index were changed significantly（P0.01）.There was no statistic significance in curative effect between two groups（P0.05）.Conclusion ACEI and ARB can significantly delay the progression of diabetic nephropathy.